Effects of Abaloparatide‐SC on Fractures and Bone Mineral Density in Subgroups of Postmenopausal Women With Osteoporosis and Varying Baseline Risk Factors

ABSTRACT Abaloparatide‐SC is a novel 34–amino acid peptide created to be a potent and selective activator of the parathyroid hormone receptor type 1 (PTHR1) signaling pathway. In the Abaloparatide Comparator Trial in Vertebral Endpoints (ACTIVE) Phase 3 trial (NCT01343004), abaloparatide reduced new...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of bone and mineral research 2017-01, Vol.32 (1), p.17-23
Hauptverfasser:	Cosman, Felicia, Hattersley, Gary, Hu, Ming‐yi, Williams, Gregory C, Fitzpatrick, Lorraine A, Black, Dennis M
Format:	Artikel
Sprache:	eng
Schlagworte:	ABALOPARATIDE‐SC Aged Aged, 80 and over Bone density Bone Density - drug effects BONE MINERAL DENSITY Female FRACTURE PREVENTION Fractures Hormone replacement therapy Humans Middle Aged Odds Ratio Osteoporosis Osteoporosis - complications Osteoporosis - drug therapy Osteoporosis - physiopathology Osteoporotic Fractures - complications Osteoporotic Fractures - drug therapy Osteoporotic Fractures - physiopathology Parathyroid Hormone-Related Protein - therapeutic use POSTMENOPAUSAL OSTEOPOROSIS Postmenopause - physiology Risk Factors RISK SUBGROUPS
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	ABSTRACT Abaloparatide‐SC is a novel 34–amino acid peptide created to be a potent and selective activator of the parathyroid hormone receptor type 1 (PTHR1) signaling pathway. In the Abaloparatide Comparator Trial in Vertebral Endpoints (ACTIVE) Phase 3 trial (NCT01343004), abaloparatide reduced new morphometric vertebral fractures by 86% compared with placebo (p –3.0), history of nonvertebral fracture (yes versus no), prevalent vertebral fracture (yes versus no), and age (
ISSN:	0884-0431 1523-4681
DOI:	10.1002/jbmr.2991